clinical trial · NCT05042258
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Atopic DermatitisSleep DisturbanceDupilumab
brief summary
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
started
Aug 12, 2024
primary completion
Jun 1, 2027
completion
Jun 1, 2027
last updated
Apr 27, 2026
detailed description
Subjects will complete two overnight sleep studies, before and after using dupilumab for 12 weeks, to assess the effect of dupilumab on sleep disturbance in eczema patients. These overnight visits will include PSG, blood draws, skin sensors, urine collection, tape stripping, and photography. Subjects will be given dupilumab to use for 12 weeks at home before returning for the second sleep study.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol